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ABSTRACT
The amyloid beta-peptide (Aβ) plays a leading role in Alzheimer’s disease (AD) 
physiopathology. Even though monomeric forms of Aβ are harmless to cells, Aβ can 
aggregate into β-sheet oligomers and fibrils, which are both neurotoxic. Therefore, 
one of the main therapeutic approaches to cure or delay AD onset and progression 
is targeting Aβ aggregation. In the present study, we show that a pool of human 
gamma immunoglobulins (IgG) protected cortical neurons from the challenge with 
Aβ oligomers, as assayed by MTT reduction, caspase-3 activation and cytoskeleton 
integrity. In addition, we report the inhibitory effect of IgG on Aβ aggregation, 
as shown by Thioflavin T assay, size exclusion chromatography and atomic force 
microscopy. Similar results were obtained with Palivizumab, a human anti-sincitial 
virus antibody. In order to dissect the important domains, we cleaved the pool 
of human IgG with papain to obtain Fab and Fc fragments. Using these cleaved 
fragments, we functionally identified Fab as the immunoglobulin fragment inhibiting 
Aβ aggregation, a result that was further confirmed by an in silico structural model. 
Interestingly, bioinformatic tools show a highly conserved structure able to bind 
amyloid in the Fab region. Overall, our data strongly support the inhibitory effect of 
human IgG on Aβ aggregation and its neuroprotective role.
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative 
process leading to irreversible dementia. The main hallmark 
of AD is the extracellular accumulation of amyloid 
β-peptide (Aβ) to form oligomers and fibrils, which are 
synaptotoxic [1–3] and induce neuronal death [4–6].
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Aβ is produced by all the cells of the organism as 
a result of amyloid precursor protein (APP) proteolytic 
processing, when it is sequentially cleaved by beta- and 
gamma-secretase complex [7–10]. Under physiological 
conditions, Aβ is produced within the brain at a low rate. 
Aβ length varies depending on its cleaving sites: Aβ
1-40
 
is the most abundant, followed by Aβ
1-42
. Additionally, 
there are larger (1-43) and N-terminal truncated (X-40 and 
X-42) Aβ species [11]. Once Aβ is released into the brain 
parenchyma it can be degraded, mostly by neprilysin [12] 
and insulin-degrading enzyme (IDE)[13]. Nevertheless, 
there are other proteolytic enzymes contributing to 
its degradation, such as plasmin [14], the angiotensin 
converting enzyme (ACE) [15] and endothelin converting 
enzyme (ECE) [16]. Monomeric Aβ that is not degraded 
is drained into the blood through the Low-Density 
Lipoprotein Receptor-Related Protein (LRP), which is in 
the basal membrane of the endothelium and releases Aβ to 
plasma by transcytosis [17]. The beta-secretase (BACE1) 
activity increases with age [18], which causes an increase 
in Aβ production. Particularly, Aβ
1-42
 levels are increased 
in the elder, probably due to the nitrotyrosination of 
gamma-secretase complex [10]. Aβ
1-42
 misfolding into 
β-sheet favours its aggregation and the formation of 
oligomers [6], preventing its drainage through the blood 
brain barrier (BBB). This aggregation also produces 
cerebral amyloid angiopathy, due to the accumulation of 
Aβ in brain vessels [19, 20].
Currently, there is no effective treatment for AD. 
However, different approaches to reduce Aβ deposition 
are being studied, including the modulation, clearance 
or inhibition of Aβ aggregation [21]. There are strong 
evidences showing that the reduction of Aβ could be 
helpful for treating AD [22, 23]. In this context, there 
are reports on immunotherapy, which relies on evidences 
showing that Aβ antibodies not only inhibit fibril 
formation, but also disassemble pre-formed aggregates 
[24, 25]. Gamma immunoglobulins (IgG) can cross the 
BBB to act in the central nervous system [26]. Different 
groups have studied the mechanism by which antibodies 
targeting Aβ N-terminal region inhibit its aggregation [24, 
27, 28]. In addition, it has been shown that peripheral 
administration of anti-Aβ antibodies could reduce brain 
plaques in an AD mouse model [26]. Several clinical 
trials using humanized monoclonal antibodies against Aβ, 
showed promising results regarding safety and tolerance 
[21, 29–33]. Although none of them has overcome phase 
III for mild to moderate AD until now [30, 31], some trials 
are still ongoing because of their potential [32, 34, 35]. 
The administration of an intravenous human serum IgG 
preparation was reported to be safe, and the treatment was 
confirmed to be present in the cerebrospinal fluid (CSF). 
Even though the treatment was effective among APOE-e4 
carriers, it was not able to overcome phase III [36, 37]. 
Recently, the humanized IgG aducanumab has obtained 
very promising results, demonstrating a decrease in brain 
Aβ that correlates with slow clinical decline [32].
Here, we report the role of the human pool of IgG 
in the inhibition of Aβ aggregation and neurotoxicity, 
independently of IgG antigen-specificity. Particularly, we 
show experimentally for the first time the importance of 
the antigen-binding fragment (Fab) in the inhibition of Aβ 
aggregation.
RESULTS
IgG prevents amyloid toxicity in cortical neurons
Ultimately, the deposition of Aβ in AD brain leads 
to neuronal death. Therefore, we have tested IgG effect on 
Aβ-mediated neurotoxicity. Aβ oligomers, resulting from 
the aggregation of Aβ
1-42,
 were prepared in the presence 
or absence of IgG, either at plasmatic physiological 
concentration (7 mg/mL) or at 0.04 mg/mL because it has 
been reported as the non-pathological IgG concentration 
in the central nervous system (CNS) [38]. We used Aβ
1-42
 
because it is the most aggregation-prone species and, in 
consequence, the most neurotoxic amyloid form [39]. The 
different treatments were administered to cortical primary 
neurons to further evaluate cell viability. Aβ
1-42
 oligomers-
mediated neurotoxicity was significantly reduced in the 
presence of 7 mg/mL of IgG, but not with IgG at 0.04 mg/
mL (Figure 1A). To confirm this observation, we analyzed 
apoptosis performing an immunofluorescence staining 
against active caspase 3 and β3-tubulin (Figure 1B). We 
observed higher levels of active caspase 3 and an altered 
neuronal morphology, characterized by less neurites in 
neurons treated with Aβ
1-42
 oligomers prepared in the absence 
of IgG. Conversely, Aβ
1-42
 oligomers prepared in the presence 
of IgG at 7 mg/mL prevented the increase in caspase 3 and 
preserved the morphology. No protective effect was observed 
when IgG at 0.04 mg/mL was co-incubated with Aβ
1-42
. 
Controls with different concentrations of IgG showed no 
effects on the viability of cortical neurons (Figure 1C).
Considering that cerebral amyloid angiopathy is 
a concomitant pathology in most of AD cases [40, 41], 
we assayed the effect of IgG on endothelial protection 
against amyloid challenge (Figure 1D). Brain vascular 
amyloid deposits are mainly composed of Aβ
1-40
 [42], 
in consequence, we used this species to perform the 
experiment. The treatment was performed using a final 
concentration of 0.1 μM because it produces a significant 
decrease in cell viability. As expected, simultaneous 
incubation of Aβ
1-40
 with 7 mg/mL of IgG protects 
endothelial cells against oligomers cytotoxicity.
IgG inhibits Aβ aggregation
After demonstrating that IgG prevents Aβ-mediated 
neurotoxicity, we were interested in elucidating the 
mechanism by which IgG mediates its protective effect. 
Therefore, Aβ
1-42
 was set at aggregation conditions in 
the presence or absence of IgG (Figure 2A). We used 
the plasmatic physiological concentration of IgG (7 mg/
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mL) and a subphysiological concentration (0.7 mg/mL). 
Thioflavin T (ThT) fluorescence was analyzed after 
96 h of aggregation assay to allow fibril formation. We 
observed a significant reduction of Aβ
1-42
 fibril formation 
in the presence of 7 mg/mL of IgG (p<0.05). To confirm 
these results, Aβ1-42 was visualized on freshly cleaved 
highly oriented pyrolytic graphite (HOPG) with atomic 
force microscopy (AFM; Figure 2B). In the untreated 
Aβ1-42 controls after 96 h of aggregation mature fibers 
could be clearly identified, as well as clusters of oligomers 
(inset in Figure 2B), whereas after co-incubation with 7 
mg/mL of IgG, there were mostly amorphous globular 
structures concomitant with a significant reduction of 
mature fibrils. Overall, these results are in agreement with 
the data obtained in ThT assays.
To study the importance of antibody’s specificity 
we used Palivizumab (Pal), a humanized IgG against 
respiratory syncytial virus [43] (Figure 2C). Aβ
1-42
 
was aggregated in the presence of Pal (7 mg/mL). The 
aggregation process was analyzed by ThT fluorescence 
after 96 h. Our results show a significant decrease in Aβ
1-42
 
fibril formation similar to the observed with the pool of 
human IgG (Figure 2A). Thus, the inhibition of amyloid 
aggregation in vitro by IgG seems to be independent of 
IgG specificity.
In order to rule out an unspecific effect of IgG, 
we measured ThT fluorescence in an aggregation assay 
of scramble Aβ
1-42
 (Aβsc; which is not able to aggregate) 
and Aβsc co-incubated with IgG at 7 mg/mL and 0.7 
mg/mL (Figure 2D). Data showed the specificity of 
ThT fluorescence on fiber formation and the absence of 
inherent fluorescence of IgG.
Finally, the presence of different amyloid aggregates 
populations was analyzed by dynamic light scattering 
(DLS, Figure 3A and 3B) and the corresponding secondary 
structure was characterized using attenuated total 
reflection Fourier transform infrared spectroscopy (ATR-
FTIR, Figure 3C and 3D). Aβ
1-42
 oligomers measurement 
by DLS showed a detectable population of high molecular 
weight (particles > 1 μm) and even larger aggregates, 
which could not be detected and that were over the 
device detection limit (sharp decay at sizes > 5 μm, top 
Figure 1: IgG protects cortical neurons against amyloid toxicity. (A) Cell viability was assayed by MTT reduction in cortical 
neurons treated with 10 μM Aβ
1-42
 or 10 μM Aβ
1-42
 + IgG at either 0.04 or 7 mg/mL for 24 h. Data are the mean ± SEM of 6 independent 
experiments. *p < 0.05 by one-way ANOVA using Newman-Keuls post-test. (B) Immunofluorescence study of cortical neurons treated with 
10 μM Aβ
1-42
, 10 μM Aβ
1-42
 + 0.04 mg/mL of IgG or 10 μM Aβ
1-42
 + 7 mg/mL of IgG for 24 h. Staining for active caspase-3 is shown in red 
and for β3-tubulin in green. β3-tubulin is an overlap of images of the same area (C) Cell viability was assayed in cortical neurons by MTT 
reduction treated with increasing concentrations of IgG for 24 h. Data are the mean ± SEM of 4 independent experiments. (D) Cell viability 
was assayed by MTT reduction in endothelial cells treated with 0.1 μM Aβ
1-40
 or 0.1 μM Aβ
1-40
 + IgG 7 mg/mL for 24 h. Data are the mean 
± SEM of 5 independent experiments. *** p < 0.001 by one-way ANOVA using Newman-Keuls post-test.
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panel Figure 3A). For IgG, there is a major population 
(ca. 17%) centered at around 13 nm, corresponding to 
the size of antibodies, and two less populated (<5%) 
fractions 500 nm and 5 μm (middle panel Figure 3A). Aβ
1-
42
 oligomers incubated with 7 mg/ml of IgG for 24h show 
two populations, one centered at 13 nm corresponding 
to IgG and a second one widely centered at 1 μm (lower 
panel Figure 3A). In Figure 3B, the size distribution 
as a function of particle volume shows that the sample 
containing Aβ
1-42
 oligomers has a dominant population at 
> 1 μm, whereas in the Aβ
1-42
 oligomers incubated with 7 
mg/ml of IgG sample two populations appear, the IgG at 
13 nm and a minor population at 2 μm. The concentration 
of IgG (7 mg/ml) compared to Aβ
1-42
 oligomers (0.4 mg/
ml) may mask the observation of aggregation in DLS, 
thus we performed ATR-FTIR in thin hydrated films, 
normalizing the signal for the protein concentration 
present in the film (Figure 3C). The Aβ
1-42
 oligomers 
spectrum shows a distinctive amyloid β-sheet band at 
1628 cm-1, which is absent in the IgG containing samples. 
To confirm that amyloid β-sheet bands were absent in 
the IgG containing samples, band narrowing using the 
spectra second derivative is shown in Figure 3D. None 
of the β-sheet bands is present in sample Aβ
1-42
 oligomers 
co-incubated with 7 mg/ml of IgG. The results obtained 
by DLS and ATR-FTIR further support that IgG prevents 
Aβ
1-42
 aggregation in vitro. Overall, these experiments 
suggest a protective effect of IgG against Aβ
1-42
 
aggregation and toxicity.
Figure 2: IgG inhibits amyloid aggregation. (A) Aggregation assay of 27 μM Aβ
1-42
 with or without IgG at 0.7 and 7 mg/mL during 
96 h. ThT fluorescence was measured at 96 h. Data are the mean ± SEM of 3 independent experiments. * p < 0.05 compared to control by 
one-way ANOVA using Newman-Keuls post-test. (B) AFM images of 88,6 μM Aβ
1-42
 (left) and 88,6 μM Aβ
1-42
 treated with 7 mg/mL of 
IgG (right) for 96 h. The inset in the left image shows a cluster of oligomers. Arrows indicate mature fibers (left) and amorphous globular 
structures (right) (C) Aggregation assay of 27 μM Aβ
1-42
 with or without Palivizumab at 7 mg/mL during 96 h. ThT fluorescence was 
measured at 96 h. Data are the mean ± SEM of 3 independent experiments. * p < 0.05 by t-student test. (D) Aggregation assay of 27 μM 
Aβ
1-42
, 27 μM Aβ
1-42
 scramble (Aβsc) and 27 μM Aβsc co-incubated with IgG at 0.7 mg/mL and 7 mg/mL. ThT fluorescence was measured 
at 96 h. Data are the mean ± SEM of 3 independent experiments.
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Fab fragment is involved in the inhibitory effects 
in Aβ aggregation
The IgG is formed by the Fab, which contains 
the antigen-binding site and it is responsible for IgG 
specificity and the crystallizable fragment (Fc). Our next 
step was to study whether IgG inhibitory effect in Aβ
1-42
 
aggregation and neurotoxicity was a property of the whole 
IgG or it relies on one of these fragments. Therefore, Aβ
1-42
 
was co-incubated, separately, with the Fab and with 
the Fc for 96 h and ThT fluorescence was measured. 
Fab and Fc concentrations were calculated based on 
IgG stoichiometry. We observed that Fab inhibits Aβ
1-42
 
aggregation in a concentration-depending manner (Figure 
4A), suggesting that it is the region that binds to amyloid. 
On the other hand, Fc did not show any effect in Aβ
1-42
 
aggregation (Figure 4B).
To explore the mechanism for non-specific binding 
of Fab-Aβ
1-42
, a rigid-body docking analysis was performed 
between a selected group of non-redundant human 
Fabs with known structure and the structure of Aβ
1-42
 
[44]. The top scored decoys show the Aβ
1-42
 peptide in 
complex with the human myeloma IgG [45] (Figure 5A) 
and the human HIV-neutralizing antibody 2F5 [46] (Figure 
5B). In both cases, Aβ
1-42
 bound through a non-specific β–β 
ladder strands-pairing, like the intra-strand interactions of 
Aβ
1-42
 peptides in fibrillation. This configuration seems 
favorable, especially in the case of human myeloma IgG, 
because the stacked β–β pairing with IgG has a Cα-Cα 
distance of 10.8±0.4Å like the Aβ
1-42
 stacking distance 
in fibrillation but higher (with more distance between 
the stacked β–strands) than other exposed β–strands of 
IgG (8.5±1Å). Combined with experimental data, this 
model suggests that IgG domains can affect fibrillation by 
binding Aβ
1-42
 peptides like a new monomer of the fiber, 
blocking its progression. Considering that fibrillation of 
Aβ
1-42
 progresses from both strand sides, this mechanism 
can also explain the concentration-dependence of the 
process, requiring two IgG to block each side of fiber 
progression (see Figure 5 and Video: https://drive.google.
com/drive/folders/0B_99pS9URra_U2dZS2dxRUJFWnM
?usp=sharing).
DISCUSSION
Different strategies have been used to control 
Aβ levels in the brain, although none of them has been 
successful. Nowadays, there are a few drugs approved for 
AD treatment. Among them, most of the approved drugs 
Figure 3: Effect of IgG on Aβ oligomerization. (A) DLS. Size distribution measured by DLS as a function of signal intensity of 
particles for 5 DLS measurements of 10 scans each. (B) Size distribution as a function of volume of the measured particles for the averaged 
measurements. The arrow indicates the presence of a low percentage population at the specified size for the mixture of Aβ plus IgG. (C) 
ATR-FTIR spectroscopy of the amide I region for the indicated samples in a thin hydrated film. All spectra are normalized by the area under 
the curve, representative of the protein amount measured in each thin hydrated film. The dotted lines indicate the wavenumber position of 
the highest intensity peaks for the samples analyzed. (D) Second derivative of the ATR-FTIR to highlight different secondary structures 
due to mathematical band narrowing [59]. The arrows indicate the position of the bands characteristic for β-sheet amyloid aggregation.
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for AD are cholinesterase inhibitors (tacrine, donezepil, 
galantamine, rivastigmine) and also, a NMDA receptor 
antagonists (memantine) [47]. However, currently there 
are not drugs capable of modulating the mechanisms of 
Aβ oligomerization for therapeutic purposes.
The present work shows that the pool of human IgG 
protects cortical neurons and endothelial cells against Aß 
cytotoxicity, and inhibits Aβ aggregation at 7 mg/mL. 
The inhibitory effect on Aß aggregation had already been 
described for some anti-Aβ antibodies [24]. The authors 
attribute this effect to its specific binding to Aβ, however 
it was not shown in which IgG fragment it resides. 
Here, we identify for the first time Fab as the fragment 
responsible for inhibition Aβ aggregation, and that this 
effect is independent of IgG specificity. Over last years, 
immunotherapy has been considered a promising approach 
to prevent amyloid plaque formation, and therefore to 
ameliorate cognitive decline in AD patients. Different 
clinical trials have been performed, but none of them have 
been able to overcome phase III [30, 31]. Nonetheless, 
there are still some anti-Aβ antibodies ongoing phase 
III trials due to their potential therapeutic effect [32, 34, 
35]. The vast majority of treatments that have been tested 
following this strategy are antibodies targeting Aβ, our 
results using a pool of human IgG and Palivizumab (Pal) 
suggest that the specificity of the antibody is not especially 
relevant for inhibiting in vitro amyloid aggregation. 
However, our results were obtained by IgG or Pal 
co-incubation with soluble Aβ, and therefore recognizing 
its native non-folded sequence. Thus, we cannot discard 
that human anti-Aβ antibodies recognizing oligomers or 
fibrils folded domains could produce beneficial results in 
AD treatment.
Clinical trials have shown that immunotherapy 
reduce Aβ amyloid deposits in the brain, besides showing 
safety and tolerance [21, 29–33]. However, they also 
Figure 4: Fab is the region that inhibits amyloid aggregation. Aggregation assay of 27 μM Aβ
1-42
 co-incubated with Fab fragment 
at 0.46 and 4.6 mg/mL (A) or Fc fragment at 2.3 mg/mL (B) during 96 h. ThT fluorescence was measured at 96 h. Mean ± SEM of 3 
independent experiments *** p < 0.001 by one-way ANOVA using Newman-Keuls post-test.
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present several significant side effects that should be 
considered. These side effects, such as cerebral amyloid 
angiopathy (CAA)-associated cerebral hemorrhage [48] or 
vascular edema [49], are primarily related to inflammation 
[50, 51]. Taking into consideration that Fc is the fragment 
responsible for triggering the immune response, 
administration of IgG could be a method to overcome 
inflammatory problems. Moreover, reducing IgG size 
could be a manner to potentiate their pass through BBB. In 
addition, intravenous IgG therapy has also been proposed 
as a treatment for AD. It has been shown to reduce Aβ 
levels in the CSF, increase its levels in serum and improve 
cognitive function, but it has not been able to conclude any 
clinical trial [36, 37, 52]. Importantly, adverse reactions to 
this treatment are not common and they are usually minor, 
including mild to moderate headache, fever, chills and 
myalgia [53]. Nevertheless, a quite promising study on a 
human anti-Aβ antibody able to recognize oligomers of 
Aβ has been recently published [32].
On the other hand, amyloid is produced by all the 
cells of the body [54], but paradoxically, Aß aggregation 
is just observed inside the brain. These evidences suggest 
that amyloid aggregation would be physiologically 
inhibited in systemic tissues and in brain, until the amount 
of amyloid exceeds a concentration threshold. Is in this 
scenario that IgG would be acting as a physiological 
inhibitor of amyloid aggregation, and therefore 
ameliorating AD condition.
Figure 5: In silico study of Aβ1-42 binding the IgG Fab region: Top scored decoys for antibody-Aβ1-42 docking. In silico 
structural modeling of the interaction between amyloid (light brown) and the functional region of the Fab domain (light blue). Top scored 
decoys for the interaction with the structure of the Fab region of myeloma IgG are shown in (A, C, E, and G,) with best to worst decoys, 
respectively. Top scored decoys for the interaction with the structure of the Fab region of HIV IgG are shown in (B, D, F, and H,) with 
best to worst decoys, respectively. Scores obtained with Rosetta are shown at the bottom of each decoy (low score Rosetta-energies indicate 
the most stable decoys).
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In conclusion, the data presented here contribute 
to the understanding of the role of IgG regarding Aβ 
aggregation. Further studies on Fab fragment may lead to 
the development of new approaches able to prevent Aβ 
oligomerization without leading to inflammation or other 
side-effect, hence being a promising treatment for AD.
MATERIALS AND METHODS
Mouse cortical primary cultures
Mouse cortical neurons were isolated from 
18-day-old CD1 embryos. The procedure was approved 
by the Ethics Committee of the Institut Municipal 
d’Investigacions Mèdiques-Universitat Pompeu Fabra 
(EC-IMIM-UPF). Cortex was aseptically dissected in ice-
cold HBSS (Life Technologies) supplemented with 4.5 
g/L glucose (Sigma-Aldrich) and trypsinized for 17 min 
at 37ºC. After 3 washes in HBSS+glucose and mechanical 
dissociation, cells were seeded on DMEM (Life 
Technologies) plus 10% horse serum (Life Technologies) 
onto 1% poly-D-Lysine (Sigma-Aldrich, USA) coated 
plates. After 2 h, medium was removed and Neurobasal 
medium (Life Technologies) was added containing 2% 
B27 supplement (Gibco BRL), 1% GlutaMAX (Life 
Technologies) and 1% Penicillin/Streptomycin. On day 
3 of culture (DIV), cells were treated with 2 μM 1-β-D-
arabinofuranosylcytosine (AraC; Sigma) for 24 h to 
eliminate proliferating non-neuronal cells. Primary cortical 
neurons were used at 10 DIV.
Porcine aortic endothelial cultures
Endothelial cells were isolated from porcine aortas 
provided by FRISELVA (Girona, Spain). Endothelial 
cells were obtained following Epithelial Cell Culture 
Protocols of Methods in Molecular Biology. Briefly, 
porcine aortas were cleaned in washing solution (HBSS 
with 0.002 mM HEPES and antibiotics) and incubated in 
collagenase solution (50 mg/mL collagenase type II, 0.1 
g/L MgCl2·6H2O, 7 g/L NaCl, 0.1 g/L Na2HPO4·7H2O, 
0.18 g/L NaH2PO4·H2O, 0.54 g/L D-Glucose and 0.2 
% FBS) for 15 minutes. Aortas were scratched into 
Endothelial Medium (DMEM F12K, 0.1 mg/mL heparin, 
10% fetal bovine serum (FBS) and 2 mM of L-Glutamine 
plus antibiotics). Cells were collected by centrifugation 
and seeded in T-75 flasks. Cells were grown in Endothelial 
Medium and were used up to passage number 8.
Aβ1-42 and Aβ1-40 preparation
Lyophilized Aβ
1-40
 or Aβ
1-42
 (Anaspec) were 
solubilized as previously described [55]. Briefly, 1 mg of 
Aβ was dissolved in 250 μL of MilliQ water and pH was 
adjusted to ≥ 10.5 using 1 M NaOH solution to avoid the 
isoelectric point of Aβ. Then, 250 μL of 20 mM Phosphate 
Buffer (pH 7.4) were added and the preparation was placed 
for 1 min in a bath-type sonicator (Bioruptor, Diagenode). 
Aβ preparation was immediately used for oligomer 
preparation or stored in 25 μL aliquots at -20ºC until used 
for ThT experiments. For oligomer preparation, Aβ was 
dissolved to 0.4 mg/mL in DMEM/F12 without phenol red 
with or without IgG (Grifols) or 6E10 (Covance).
IgG preparation
The pool of human IgG was provided by Grifols 
(Flebogamma® 5% DIF; 100 mL).
Cell viability assay by MTT reduction
Cortical primary neurons and endothelial cells were 
seeded in a 96-well plate at a density of 1x104 cells/well. 
The treatment (100 μL/well) was added to Neurobasal 
without phenol red supplemented with 1% GlutaMAX 
(Life Technologies) for cortical neurons and Endothelial 
Medium without FBS for endothelial cells. Cells were 
treated for 24 h at 37ºC. Cell viability was tested by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reduction. Briefly, 11 μL of MTT stock 
solution (Sigma Aldrich; 5 mg/mL) were added. After 2 
h the media was replaced with 100 μL of DMSO. MTT 
absorbance was determined in an Infinite 200 multiplate 
reader (Tecan) at A540 nm and corrected by A650 nm. 
Untreated cells were taken as 100%.
Immunofluorescence
Cortical primary neurons (1x105 cells/well) were 
fixed with 4% paraformaldehyde and permeabilized 
with 0.1% Triton X-100 for 10 min at RT. Samples were 
blocked with 5% Fetal Bovine Serum, 1% albumine from 
bovine serum and 0.02% sodium azide overnight at 4ºC. 
Subsequently, coverslips were incubated for 2 h at RT in a 
hydration chamber with the following primary antibodies: 
anti-β3 tubulin (1:200; Cell Signalling) and anti-cleaved 
Caspase-3 (1:100; Abcam). Then, samples were washed 
thrice with PBS and incubated with Alexa Fluor 488 goat 
anti-mouse and Alexa Fluor 555 goat anti-rabbit antibodies 
(1:1000; Life Technologies) for 1 h at RT. Coverslips were 
mounted and analyzed using a Leica TCS SP5 confocal 
microscope (63x objective) and analyzed with Leica 
confocal software.
Thioflavin T binding assay
A 1 mM stock ThT (Sigma Aldrich) solution was 
prepared dissolving the dye in PBS. The solution was 
filtered using a 0.22 μm syringe filter. ThT solutions 
were stored at -20ºC in the dark. Aβ
42
 peptide (27.5 
μM) was incubated with or without IgG (0.7 and 7 mg/
mL; Grifols), Palivizumab (7 mg/mL; Synagis), Fab (4.6 
mg/mL; Grifols) and Fc (2.3 mg/mL; Grifols) and 10 
μM ThT in a Nunc-96-well flat bottom black polystrol 
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microplate (Thermo Scientific) at 37ºC. ThT fluorescence 
was measured at 96 h using excitation and emission 
wavelengths of 430 and 470 nm, respectively, using a 
multiplate reader fluorimeter (FLUOstar optima, BMG 
labtech).
Atomic force microscopy
A MultiMode atomic force microscope (Veeco 
Instruments Inc., Santa Barbara, CA) equipped with a 12 
mm scanner (E-scanner) was used to analyze Aβ samples 
aggregated with or without IgG for 96 h. Sample aliquots 
were frozen and were thawed at RT just before the AFM 
experiments. The images were taken in liquid with a liquid 
cell without the O-ring seal. 5-10 mL of sample were 
deposited on cleaved mica substrates. After an adsorption 
time of 5 min, 40 mL of double deionised water were 
added to form a drop suitable for the imaging procedure. 
The system was left for equilibration for at least 10 min 
before carrying out the experiments. NP-S (Veeco) probes 
were used to scan the samples in tapping mode at 0.5 Hz 
scan rate. Height and amplitude images were recorded 
simultaneously, although only the latter are presented in 
this paper.
DLS measurements
Samples were prepared as indicated above and kept 
for 24 h at 4ºC. DLS measurements were recorded on a 
Zetasizer instrument (Nano ZS; Malvern Instruments) at 
20º C using a small volume (40 μL) quartz cuvette of 1 cm 
path length. Scattering data were collected as an average 
of 5 measurements with 10 scans for each measurement. 
Refractive indices were 1.330 (water) and 1.45 (protein) 
for polydispersant and material, respectively. Data were 
processed with the Malvern Zetasizer Software (Malvern 
Instruments).
ATR-FTIR spectroscopy
Thin hydrated films of samples placed on top of the 
ATR diamond crystal were prepared under a N2 stream 
gentle drying. Spectra were obtained at RT by the average 
of 250 scans at 2cm-1 resolution in a VARIAN FTS-
7000 infrared spectrometer. The second derivative was 
performed with ten smoothing points.
Size exclusion chromatography
Size exclusion chromatography was performed 
in an AKTA purifier FPLC system. All chromatograms 
were run at 4ºC using a flow of 0.4 mL/min in 10 mM 
Tris·HCl buffer pH 7.4. An initial run in a Superdex 75 
10/30 column was performed to separate HMW and LMW 
aggregates. HMW aggregates were injected in a Superose 
6 10/30 column to analyze the size exclusion profile of the 
non-resolved species.
Fab and Fc fragments purification
To obtain Fab and Fc fragments of IGIV 
Flebogamma® DIF 5% 100 mL, the commercial Fab 
preparation kit (Pierce) was used following manufacturer 
instructions and the molecular distribution analysis 
method MA_IG-000158A was used. Briefly, 500 μL of 
IGIV (8 mg/mL) were desalted by Zeba™ Spin Desalting 
Column following the kit instructions, while 250 μL 
agarose resin with immobilized papaine, previously 
packed in a 0.8 mL column, were equilibrated with a 
digestion buffer (cysteine·HCl 3.5 mg/mL pH 7). Once 
equilibrated, 500 μL of desalted IGIV were added and 
maintained in agitation at 900 rpm for 10 h at 37ºC. Then, 
the microcolumn was centrifuged and washed with PBS 
at 5000 g for 1 min to separate completely the digest and 
the agarose resin.
To purify the Fab fragment from de digest, it was 
added to a NAb™ Protein A Spin Column, previously 
equilibrated, and incubated for 10 min at RT. After the 
incubation, Fc fragments and undigested IgGs were 
retained at the column, while Fab purified fragments were 
collected with flow through. To recover Fc fragments and 
undigested IgGs, NAb™ Protein A Spin Column was 
eluted. The eluted was concentrated to 6 mg/mL of protein 
using Ultracel YM-3 filters 3 kDa NMWL (Millipore). 
Then, it was injected to an exclusion molecular column 
TSKgel G3000 SW 60 cm X 7.5 mm. I.D. (Teknokroma) 
in order to be fractioned with a high-performance liquid 
chromatography (HPLC) Waters 2695 Separations Module 
(Alliance) with UV detector diodo-array Waters 996. After 
16.5 min, Fc purified fraction was recollected for 1 min. 
Finally, Fab and Fc purified fragments were concentrated 
using Amicon Ultra-15 filters 3 kDa NMWL (Millipore).
Computational analysis of the IgG-amyloid 
interaction
All human IgGs with less than 70% sequence 
identity and known structure were retrieved with the 
Protein Data Bank REST service [56]. From this search, 
two non-redundant representatives of the IgG Fab 
region were found: the human myeloma IgG (PDB: 
8FAB) [45] and the human HIV-neutralizing antibody 
2F5 (PDB:2F5B) [46]. These two structures were tested 
individually by performing rigid-body docking with the 
structure of Aβ
1-42
 obtained by solid-state NMR (PDB: 
2LNQ) [44].
Around 19000 decoys of the complex IgG-Aβ
1-42
 
were obtained for each IgG (2LNQ-8FAB and 2LNQ-
2F5B) with PatchDock [57]. We selected the top 100 
decoys of PatchDock to calculate the binding ΔG with 
Rosetta [58]. We selected the top 4 decoys with higher 
binding affinity for each tested IgG.
The final selected models depict the conformations 
of Aβ
1-42
 interacting with the human myeloma IgG 
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(Figures 5A, 5C, 5E, 5G) and the human HIV-neutralizing 
antibody (Figures 5B, 5D, 5F, 5H). The best scored decoys 
(Figures 5A, 5B) show the interaction between Aβ
1-42
 
and the IgG Fab region through the pairing of β-strands, 
extending the Ig-like fold core β-sheet. The non-specific 
pairing of β-strands can be seen in other top scored decoys 
(Figures 5C, 5F, 5G, 5H), although in these decoys only 
one β-strand of Aβ
1-42
 binds the β-sheet of the IgG fold, 
reinforced with other side-chain contacts. All decoys show 
the molecular mechanisms by which the IgG Fab region 
blocks the progression of the fiber: either playing the role 
of a new Aβ
1-42
 monomer, or avoiding the attachment of 
new Aβ
1-42
 monomer due to steric hindrances.
Statistical analysis
Data are expressed as mean ± SEM of n experiments 
as indicated in the corresponding figures. Statistical 
analyses were performed by one-way ANOVA or t-student 
using GraphPad software. * p < 0.05; *** p < 0.001.
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